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Abstract.  Interleukin  10 (IL-10) suppressed 'I'GF-/3 
synthesis in mouse bone marrow cultures.  Coincid- 
ingly,  IL-10 down-regulated the production of bone 
proteins including alkaline phosphatase (ALP), colla- 
gen and osteocalcin, and the formation of mineralized 
extracellular matrix.  The mAb 1Dll.16 which neutral- 
izes TGF-/31 and TGF-/~2,  induced suppressive effects 
comparable to IL-10 when administered before the in- 
crease of cell proliferation in the culture.  It appears 
that mainly TGF-B1  plays a role in this system since 
(a) TGF-/T2 levels were undetectable in supernatants 
from osteogenic cultures,  (b) no effect was observed 
when the anti-TGF-B2  neutralizing  mAb 4C7.11  was 
added and (c) the suppressive effect of IL-10 could be 
reversed by adding exogenous TGF-/31. It is unlikely 
that TGF-B1  modulates osteogenic differentiation by 
changing the proliferative potential of marrow cells 
since  1Dll.16 did not affect [3H]thymidine ([3H]TdR) 
incorporation or the number of fibroblast colony form- 
ing cells (CFU-F) which harbor the osteoprogenitor 
cell population.  Furthermore,  1Dll.16 did not alter 
[3H]TdR uptake by the cloned osteoprogenitor cell 
lines MN7 and MC3T3.  Light and scanning electron 
microscopy showed that IL-10 and  1Dll.16 induced 
comparable morphological changes in the marrow cup 
tures.  Control cultures contained flat adherent cells 
embedded in a mineralized matrix.  In contrast,  IL-10 
and  1Dll.16 treated cultures were characterized by 
round non-adherent calls and the absence of a miner- 
alized matrix.  In this study, the mechanism by which 
IL-10 suppresses the osteogenic differentiation of 
mouse bone marrow was identified as inhibition of 
TGF-/~I  production which is essential for osteogenic 
commitment of bone marrow cells. 
ONE marrow stroma forms a network of fibroblasts, 
adipocytes, endothelial cells, and macrophages which 
supports and regulates  hemopoiesis (Dexter et al., 
1982; Allen et al., 1984) and harbors cells of the osteogenic 
lineage (Friedenstein  et al.,  1976; Owen et al.,  1980). The 
latter is illustrated by the fact that marrow cells differentiate 
into bone when transplanted  in ectopic sites (Ashton et al., 
1980;  Friedenstein,  1980;  Budenz and Bernard,  1980) or 
when cultured in the presence of vitamin C and/3-glycero- 
phosphate (Howlett et al.,  1986;  McCulloch et al.,  1991; 
Falla et al.,  1993). In addition,  a number of immortalized 
and  transfected  cell  lines  generated  from  bone  marrow 
stroma elicited osteogenic characteristics  in culture or when 
transplanted  in vivo (Benayahu et al.,  1989; Mathieu et al., 
1992). 
Although  IL-10 was first described as "cytokine synthesis 
inhibiting  factor" (CSIF)  1 (Fiorentino  et al.,  1989),  subse- 
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quent studies revealed its pleiotropic activities.  Apart from 
suppressing  cytokine synthesis by murine Type 1 helper T 
cells (De Waal Malefijt et al., 1991a) and macrophage  func- 
tions (De Waal Malefijt et al.,  1991b), IL-10 stimulates  the 
growth of  mast cells (Thompson-Snipes  et al., 1991), B cells 
(Go et al.,  1990),  and thymocytes (MacNeil et al.,  1990). 
We recently demonstrated that IL-10 is a potent inhibitor of 
the osteogenic  activity of murine bone marrow (Van Vlas- 
selaer et al.,  1993).  This  study revealed  that by acting  on 
early steps  of osteogenic differentiation,  IL-10 suppresses 
the  synthesis  of several  bone proteins  including  alkaline 
phosphatase (ALP), collagen type I and osteocalcin,  and the 
potential  of cultured marrow to form a mineralized  matrix. 
Hence IL-10 joins the list of cloned factors able to influence 
bone biology. 
One aspect of the complex mechanisms governing  bone 
formation is the network of  osteotropic cytokines and growth 
factors (Gowen,  1992). Among them TGF-B was shown to 
elicit a  broad range of biological activities  (Sporn  et al., 
lagenase digestible protein; CFU-F,  fibroblast colony-forming cells; CSIF, 
cytokine synthesis inhibiting factor. 
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and differentiation of several cell types specific to bone in- 
cluding mesenchymal precursor cells, chondrocytes,  osteo- 
blasts, and osteoclasts (Noda and Rodan,  1986; Centrella et 
al.,  1987a; Gehron-Robey et al., 1987; Wrana et al.,  1988; 
Shinar and Rodan, 1990; Joyce et al., 1990; Noda and Camil- 
liere, 1989). TGF-/3 is synthesized by osteoblasts (Gehron- 
Robey et al.,  1987), and is present in large amounts in the 
bone matrix where it may serve as a reservoir  (Hauschka 
et al., 1986) and control the osteogenic differentiation of"na- 
ive" mesenchymal cells. In support of this view, TGF-/3 was 
reported  to  regulate  chondrogenesis  from  mesenchymal 
cells (Gehron-Robey  et al., 1987; Seyedin et al.,  1987) and 
to modulate the expression of the osteoblast phenotype in 
vitro (Rosen et al., 1988). In addition, immunohistochemical 
staining and in situ hybridization  revealed accumulation of 
TGF-/3 in areas of endochondral  ossification (Carrington et 
al.,  1988). 
The goal of this study was to define the mechanism of ac- 
tion by which IL-10 suppresses bone protein synthesis  and 
the formation  of mineralized  matrix in cultures  of mouse 
bone marrow. This study showed that IL-10 activity resulted 
from its inhibitory  effect on the synthesis  of TGF-/SI which 
appears to be a crucial factor for the initiation of osteogenic 
differentiation of mesenchymal cells from the mouse bone 
marrow. 
Materials and Methods 
Mice and Bone Marrow Cell Preparation 
Eight to ten week old BALB/c mice were administered 5-Ruoreuracil  (5- 
FU) (Roche) at 150 mg/kg body weight by tail vein injection. 5 d later the 
marrow was flushed from the femora and dispersed into a single cell suspen- 
sion. Red blood cells were removed by density centrifugation on a 70% Per- 
cull (Pbarmacia,  Sweden) gradient. 
Cell Culture 
Bone marrow cells were cultivated in fiat bottom 96 well plates at 5 ×  104 
cells per well in ISCOVE's medium supplemented with 10% FCS, L-glnta- 
mine, penicRlin and streptomycin, ascorbic acid (100 ~g/ml), and fl-glyc- 
erophospbate (0.6% wt/wD. Purified, recombinant murine IL-10 was added 
at a concentration of 2.5  x  103 U/m1. To determine cell proliferation, cul- 
tures were pulsed with [3H]TdR (1 ~,Ci/wall) for 18 h, and were then har- 
vested and read in a liquid  scintillation counter. The anti-TGF-8 mAbs, 
11)11.16 and 3C7.14 (Dash et al., 1979), were added at a final concentration 
of 10 ~g/mi at time points indicated in the text.  1Dl1.16 neutralizes the 
activity of TGF-/~I and TGF-I~2 whereas 3C7.14 neutralizes the activity of 
only TGF-0"2. 
Quantitation of Fibroblast 
Colony-forming Cells 
The number of CFU-F was scored as described by Van Den Heuvel et al. 
(1987). Bone marrow cells were plated at 5 ×  I0  4 cells per 35-mm culture 
dishes. Replicate cultures were incubated at 37°C for 10 d and were then 
fixed with methanol and stained with May-Grunwald-Giemsa. Colonies of 
fibroblastoid cells were scored under a binocular  (20x). 
TGF-f3 Quantitation 
TGF-~I was determined by measuring the inhibition of growth of the mink 
lung cell  line  MvlLu as  described by Danielpour et al, (1989). MvlLu cells 
were plated at 103 cells per well in flat bottom 96 well plates and allowed 
to adhere. Samples were added without treatment and after acidification. 
Acid activation of the supernatants was performed by the addition of HC1 
to reach pH 1.5 for 1 h. The medium was then renentralized using NaOH. 
After  72 h of  cultivation,  cell  proliferation  was determined using  the MTT 
assay described by Mossman (1983). The suppressive effect of the culture 
supernatants on MvlLu cell growth was reversed with IDll.16  (10 pg/ml) 
indicating that the suppressive activity was due to TGF-~ activity. "IX3F-~ 
was quantitated in comparison with a dose response curve using a standard 
of biologically active TGF-O (British Biotecbuology, UK). The amount of 
"rGF-01 and "rGF-/~2 in the samples was discriminated by adding the TGF-/~ 
neutralizing  mAbs  11)11.16 and  3C7.14 separately.  IDII.16  blocks both 
TGF-~I and "rOF-jff2  whereas 3C7.14 blocks specifically the activity of  TGF- 
7b2 but not of TGF-/31. The sensitivity of the assay was 1 pg/ml. The con- 
centrations of TGF-~I and TGF-~2 were determined in the FCS used in the 
medium and was subtracted from the experimental values. Consequently 
the results represent the amount of  TGF-~ secreted in the cultures. Both an- 
tibodies  showed cross species specificity and were able to block bovine 
TGF-31 and TGF-32. 
Measurement of  ALP Activity 
ALP activity was determined on day 15 of  the culture as described by Lowry 
et al. (1954). The cultures were incubated with 0.1 M sodium acetate solu- 
tion supplemented with 0.1% Triton X-100 and 5 mM p-nitrophenol phos- 
phate (Sigma 104), pH 9.6 for 1 h at 37°C. Absorbance was determined at 
405 nm and compared to a p-nitrophenol standard titration curve. ALP ac- 
tivity was expressed as nmol of p-nitrophenul  formed per rain. 
Collagen Synthesis 
Collagen synthesis was measured on day 18 of  the culture by the incorpora- 
tion of [3H]proline (Amersham,  UK) into collagenase digestible protein 
(CDP) (Peterkovsky and Diegelmann, 1985). Cell cultures were incubated 
with [3Hlproline (1 pCi/well) for 18 h at 37°C, and then were washed three 
times with PBS. Collagenase (0.1 mg/ml) was added for 1 h and the CDP 
was measured in a liquid scintillation counter. Collagennse was purchased 
from Worthington (UK) and was substantially free of nonspecific protease 
activity. 
Osteocalcin Cell ELISA 
The osteocalcin cell ELISA was performed as described by Van Vlasselaer 
(1992). The cultures were fixed with 4% cold formaldehyde for 30 rain at 
4°C, and then were washed with TRIS/HCI buffer (0.05 M pH 7.6). Endoge- 
nous peroxidase activity was blocked with 3 % H202 for 5 rain. The sam- 
ples were then rinsed with TRIS/HCi buffer and blocked with normal goat 
serum (1:5 dilution, TACK)) for I h at 37°C. Rabbit-anti-mouse osteocalcin 
antiserum  (kindly provided by Dr. R. Bouillon,  K.U. Leuven, Belgium) 
was added (1:5,000 dilution) for 2 h at 4°C. The cultures were washed with 
TRIS/HC1 buffer and incubated with HRP-conjugated goat-anti-rabbit  Ig 
serum (1:2,000 dilution, TACK)) for 30 rain at 4°C. After riming, the cul- 
tures were incubated at 37°C with substrate solution (ABTS, 1 mg/ml + 
H202 0,I ul/ml ill citric  acid/Na2HPO4,  10,5  gr/14.2  gr/500 mi 1"120)  until 
coloration  occurred. Absorbance was read  at  450 nm with a reference  of 
650 urn.  Osteocalcin  was quantitated  on day 24 of culture.  Non-specific 
binding of  the anti-mouse osteocalcin antiserum was determined using non- 
immune rabbit serum  under the same conditions. The amount of  osteocalcin 
incorporated in the culture was determined in comparison with a standard 
ELISA of purified mouse osteocalcin (kindly provided by Dr. R. Bouillon, 
K.U. Leuven, Belgium). The sensitivity of this assay was 0.3 rig/m1. No 
cross reactivity was observed with FCS. 
Calcium Determination 
Calcium was determined on day 27 of culture as described by Gitelman 
(1967). The cell cultures were washed with Ca  2+ and Mg  2+ free PBS and 
incubated overnight with 0.6 N HCI. The extracted calcium was complexed 
with o-cresob~thal  'em-complexon  (Test Combination Calcium, Boehringer 
Mannheim, Germany). The colorimetric reaction was read at 570 rim. The 
absolute calcium concentration was determined in comparison with a stan- 
dard curve for calcium provided by the vendor. 
RNA Preparation and Northern Blot 
Total  cellular  RNA was prepared from 6-d old cultures  by acid  guauidine 
thiocyanateJphenol/cldoroform extraction  as described by Chomczynski 
and Sacchi (1987). RNA  was fractiooated  by electrophoresis  in 1.5% 
agar~e containing  I0  mM  sodium  phosphate  after  danamration  with  glyoxal 
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to a 32P-labeled  "rGF-/3 cDNA probe (Derynck et al.,  1986). Autoradio- 
graphic exposure was performed onto Kodak Ortho G X-ray films. Densi- 
tometry analysis was performed on a  Imagestore 5000 device using SW 
5000 software for analysis (Ultraviolet Products,  Ltd.,  Cambridge,  UK). 
Results 
Effect of  lL-lO on TGF-[3 Synthesis 
We previously showed that IL-10 suppresses in vitro bone 
protein synthesis and the formation of mineralized matrix in 
cultures  of mouse  bone  marrow  (Van  Vlasselaer  et  al., 
1993).  Based on the CSIF activity of IL-10 and the role of 
TGF-/3 in bone biology, the question addresses whether IL-10 
exerts  this  suppressive  effect by  down-regulating TGF-/3 
production. To this end TGF-B concentrations were mea- 
sured in marrow cultures performed in the absence or pres- 
ence of IL-10 (2.5  x  103  U/rnl).  Supernatants were col- 
lected  at  3-d  intervals  and  their  inhibitory activity was 
determined on the TGF-/3 sensitive MvlLu mink lung cell 
line. Biologically active and biologically inactive TGF-/3 was 
discriminated by adding the samples without previous treat- 
ment or after acidification, respectively. The levels of TGF- 
/31 and TGF-/32 were determined independently  by neutraliz- 
ing total TGF-/3 activity with the 11)11.16 and 3C7.14 mAbs 
separately. Fig. 1 shows that whereas no detectable levels of 
TGF-/~2 were observed, TGF-/31 is synthesized throughout 
the culture period with maxima around days 6 and 27. In ad- 
dition, the supernatants inhibited the growth of MvlLu cells 
without previous acidification indicating that at least part of 
the secreted TGF-/5'I is present in its biologically active form. 
During maximal synthesis, biologically active TGF-fll was 
present at concentrations of 0.015 and 0.021 ng/ml.  This 
represents ,023 % of the total amount of TGF-/5'I released in 
the medium. Hence the bulk of secreted TGF-/31 is present 
in  its  biologically inactive  form.  TGF-/31 concentrations 
were significandy reduced in IL-10-treated cultures. At days 
6 and 27, the amount of latent TGF-/5'I was reduced up to 68 
and 72 %, and the amount of active TGF-/31 up to 99 and 
90%, respectively (Fig. 1). The suppressive activity of  IL-10 
on  TGF-/5'I synthesis  was  furthermore  illustrated  at  the 
mRNA level. After 6 d of culture, the total amount of TGF- 
/31 mRNA is reduced for 40% in the IL-10-treated cultures 
(Fig. 2). Whereas this correlates with the only partial reduc- 
tion of biologically latent TGF-/31 protein observed at the 
same time point of the culture, this appears to represent an 
almost complete reduction of the amount of biologically ac- 
tive protein (Fig.  1). 
Effect of 1D11.16 and 3C7.14 on Bone Protein Synthesis 
and Mineralization 
Thus far the data suggest that in vitro osteogenic differentia- 
tion of mouse bone marrow cells is regulated in particular 
by endogenous TGF-/31 and not by TGF-/32. To further ad- 
dress this idea, cultures were performed in the absence or 
presence  of the  TGF-/3 neutralizing  mAbs  1Dll.16  and 
3C7.14 (both used at 10 #g/ml) and the degree of ALP activ- 
ity, collagen and osteocalcin synthesis, and the amount of 
matrix-bound calcium was determined at days 18, 21, 24, and 
27, respectively. Fig. 3 shows that the synthesis of the differ- 
ent  bone  proteins  and  the  degree  of mineralization was 
significantly  reduced  in  cultures  treated  with  1Dll.16. 
Whereas  ALP activity and collagen  synthesis were  sup- 
pressed  by  '~,35%,  the  effect of  1Dll.16  was  more  pro- 
nounced on osteocalcin synthesis and mineralization which 
were reduced by more than 95 %. In contrast, the addition 
of the TGF-/32 neutralizing mAb 3C7.14 did not alter bone 
protein synthesis and mineralization. Taken together this il- 
lustrates once more that endogenous TGF-/32 plays no role 
during in vitro osteogenic differentiation  of  mouse bone mar- 
row cells (Fig. 3). 
Reversal of  lL-lO Activity by TGF-BI 
The possibility that IL-10 suppresses bone protein synthesis 
and mineralization by blocking TGF-/31 production was fur- 
ther analyzed. Cultures were performed in the presence of 
IL-10 and supplemented from the start with exogenous TGF- 
/31 (1 ng/ml). ALP, collagen and osteocalcin synthesis, and 
the degree of mineralization were determined at the time 
point of their maximal expression, e.g., at days 15,  18, 24, 
and 27 of culture, respectively (Falla et al., 1993). Whereas 
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Figure 1.  Effect of IL-10 on 
TGF-31 and TGF-/32 synthe- 
sis. Cultures were set up un- 
der  standard conditions and 
supernatants were collected at 
3-d intervals. Biologically in- 
active and active TGF-/~I and 
TGF-/32 were determined us- 
ing the MvlLu cell growth in- 
hibition assay, o and [] repre- 
sent TGF-/31 levels in control 
and IL-10 (2.5  ×  103 U/ml) 
treated cultures, respectively. 
and  •  represent TGF-ff2 
levels  in  control  and  IL-10 
(2.5 ×  103 U/ml) treated cul- 
tures,  respectively. The  re- 
suits represent the mean + SD 
of triplicate cultures of one 
representative experiment. 
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cells were cultured for 6 d under standard conditions and the ex- 
pression of TGF-/31 mRNA was determined by Northern blot anal- 
ysis. Lanes 1 and 2 represent mRNA from untreated and IL-10 
treated cultures, respectively. 
IL-10 reduced ALP activity and collagen synthesis for 54 and 
40 %, the suppressive effect  was most obvious on osteocalcin 
synthesis and mineralization where IL-10 elicited suppres- 
sions up to 90%. The addition of exogenous TGF-$ abol- 
ished this IL-10 suppressive effect completely and resulted 
in  normalized bone  protein  synthesis  and  mineralization 
(Fig. 4). In addition it is of interest to note that bone protein 
synthesis and mineralization was slightly increased in con- 
trol cultures supplemented with TGF-ffl. 
Differential Effects of 1D11.16 on Early and Late Stages 
of Osteogenic Differentiation 
It is conceivable that although TGF-/31 is continuously pres- 
ent in marrow cultures, its role during osteogenic differentia- 
tion is restricted to a defined time period. Indeed, additional 
studies showed that the potential of 1Dll.16 to elicit suppres- 
sive effects depended on the moment of its addition to the 
culture.  When  1Dll.16  was  added before day  10,  it  sup- 
pressed ALP activity and collagen synthesis for 51%  and 
48% and blocked osteocalcin synthesis as well as mineral- 
ization for more than 90%.  On the other hand 1Dll.16 ex- 
erted no effect  when it was added at later time points (Fig. 5). 
Effect of 1D11.16 on Cell Proliferation 
and CFU-F Frequency 
In vitro osteogenic differentiation is preceded by a sharp in- 
crease  followed by  a  rapid  decrease  in  cell  proliferation 
(Owen et al.,  1990; Falla et al.,  1993). Consequently, one 
pathway via which TGF-/Yl may induce osteogenic differenti- 
ation is by modulating cell proliferation. To address this pos- 
sibility, marrow cultures were performed in the absence and 
presence of 1Dll.16 and the degree of [3H]TdR incorpora- 
tion was determined at 3-d intervals. Fig. 6 shows that cell 
proliferation in control cultures was maximal between days 
9 and 12, e.g., beyond the time point at which TGF-~ exerts 
its osteoinductive activity. However, the presence of endoge- 
nous TGF-~ is not required for cell proliferation since the 
level of [3H]TdR uptake was comparable between control 
and  1Dll.16 treated cultures (Fig.  6).  In addition, CFU-F 
frequency in the marrow (Fig.  7) and  [3H]TdR uptake by 
the cloned osteogenic cell lines MN7 (Mathieu et al., 1992) 
and MC3T3 (Sudo et al., 1983) were not affected  by 1Dll.16 
(Fig. 8). Hence, it is unlikely that endogenous TGF-ffl in- 
duces osteogenic differentiation  by influencing the prolifiera- 
tion of osteoprogenitor ceils. 
Morphological Changes in IL-IO and 1Dli.16 mAb 
Treated Marrow Cultures 
Coinciding with their suppressive activity, IL-10 and 1Dll.16 
significantly changed the morphology of stroma cultures. 
Light microscopy revealed that  18<1 old control cultures 
were composed of predominantly flat adherent cells. In con- 
trast,  1Dll.16 treated cultures contained large numbers of 
round non-adherent cells which formed cell aggregates in 
close contact with an adherent layer of fibroblastic and retic- 
ular cells (Fig. 9). In addition, scanning electron microscopy 
of  25-d old cultures revealed a prominent mineralized collag- 
enous extracellular matrix in the control but not in the IL-10 
and 1Dll.16 treated cultures. The density of the mineralized 
matrix present in the control cultures at that time point made 
it  impossible  to  distinguish  individual  cells.  In  contrast, 
IL-10 and 11)11.16 treated cultures were composed of large 
flat cells and small round cells with in between unoccupied 
areas.  These observations illustrate  again  the  suppressive 
effect of IL-10 and  1Dll.16 on bone protein synthesis and 
mineralization. 
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Figure  3.  Effect  of the  neu- 
tralizing  anti-TGF-B  mAb, 
1Dll.16,  and 3C7.14 on bone 
protein synthesis and mineral- 
ization.  Cultures  were  per- 
formed under standard condi- 
tions and 1I)11.16 and 3C'/.14 
mAb  were  added  from  the 
start at a final concentration  of 
10 t~g/ml. ALP activity, colla- 
gen and osteocalcin synthesis, 
and mineralization  were quan- 
titated on days 18, 21, 24, and 
27, respectively.  Control cul- 
tures  received  no  antibody. 
The  results  represent  the 
mean +  SD of quadruplicate 
cultures of one representative 
experiment. 
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Figure 4.  Effect of exogenous 
TGF-B1 on  the  suppressive 
activity  of  IL-IO. Cultures 
were set up in the absence or 
presence of IL-10 (2.5  ×  l& 
U/ml).  TGF-B  was  added 
from the start of the culture at 
a  concentration of  1 ng/ml. 
ALP activity, collagen and os- 
teocalcin synthesis,  and min- 
eralization  were  quantitated 
on days  18,  21,  24,  and 27, 
respectively.  The results  rep- 
resent the mean +  SD of qua- 
druplicate cultures of one rep- 
resentative experiment. 
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Figure  5.  Effect  of temporal 
addition  of  the  neutralizing 
anti-TGF-B mAb,  1Dll.16 on 
ALP activity, collagen and os- 
teocalcin synthesis,  and min- 
eralization.  1Dll.16  (10  #g/ 
ml) was added at 5-d intervals 
starting at Day O. Control cul- 
tures  received  no  antibody. 
The  results  represent  the 
mean +  SD of quadruplicate 
cultures of one representative 
experiment. 
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Discussion 
Mouse bone marrow cells synthesize bone proteins including 
ALE collagen and osteocalcin, and form a mineralized ex- 
tracellular matrix when cultured in the presence of/3-glyc- 
erophosphate and vitamin C. In a previous report we showed 
that these phenomena were inhibited in the presence of IL-10 
(Van Vlasselaer et al.,  1993). The goal of this study was to 
determine the mechanism of action by which IL-10 elicits 
these suppressive effects. Work by others showed that IL-10 
inhibits the production of a variety of cytokines which have 
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Figure  7. Effect of the neutralizing anti-TGF-~ mAb, IDl1.16 on 
CFU-F frequency. Marrow cells were plated at 5  x  I04 cells per 
plate and grown for 10 d in the absence or presence of 1DlI.16 (10 
izg/ml) (~-TGF). Subsequently they were stained with May-Grun- 
wald-Giemsa and the number of fibroblast colonies was counted. 
The results represent the mean +  SD of.quadruplicate cultures of 
one representative experiment. 
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Figure 8, Effect of  the neutralizing anti-TGF-~  mAb, 1Dl1.16 on the 
proliferation of the osteoprogenitor cell lines MC3T3 and MN7. 
1Dll.16 (10 #g/ml) was added from the start of the culture. White 
and black bars represent control and 1DII.1 6 (10 #g/ml) treated 
cultures, respectively. The ceils were plated at 5  x  103 cell per 
well and cell proliferation was determined 24 h later. The results 
represent the mean  +  SD of quadruplicate cultures of one ex- 
periment. 
been implicated in bone modulation, e.g., IL-1, IL-6, TNF-o~, 
and GM-CSF (Fiorentino et al.,  1991; Bodgan et al., 1991). 
In addition, this report illustrates that ILoI0 inhibits endoge- 
nous TGF-~ synthesis in osteogenic bone marrow cultures. 
This appears to be especially the case for TGF-/31 since no 
detectable levels of biologically latent or  active TGF-~2 
could be observed in the supernatants of the osteogenic cul- 
tures. Consequently this suggests that TGF-/32 plays no cru- 
cial role during in vitro osteogenic differentiation of mouse 
marrow cells. The necessity of endogenous TGF-~I for in 
vitro osteogenic differentiation was furthermore illustrated 
using the TGF-13 neutralizing mAbs  1Dll.16 and 3C7.14. 
1Dll.16 neutralizes the biological activity of both TGF-~ 
and TGF-/32 (Dasch et al.,  1989). Both forms are abundant 
in bone tissue and elicit multiple comparable effects on skel- 
etal cells in vitro (Wrana et al., 1988). However in this cul- 
ture system it appears only to be TGF-/31 which is of impor- 
tance since the TGF-/~2 specific neutralizing system it appears 
only to be TGF-/5'I which is of importance since the TGF-B2 
specific neutralizing rnAb 3C'/.14 was unable to block in vitro 
osteogenic differentiation. This is not surprising since no de- 
tectable amounts of  either biologically latent or active TGF-15~2 
were observed in supernatants from osteogenic cultures in 
the first place. In addition, TGF-/31 mRNA levels were re- 
duced in IL-10 treated as compared to untreated cultures. At 
this point it is unclear whether this is the result of a direct 
inhibitory effect of IL40 on TGF-/~I gene transcription or 
merely the result of a reduction of the number of TGF-~I se- 
creting cells. Although each of these possibilities neexls fur- 
ther investigation,  IL-10 was shown not to induce quantitative 
changes in the stromal compartment (CFU-F) but rather to 
direct stromal differentiation away from bone development 
(Van Vlasselaer et al., 1993). Although 1L40 reduces TGF- 
/31 mRNA levels for only 40%, at the protein level this repre- 
The Journal of Cell Biology, Volume  124, 1994  574 Figure 9. Effect of IL-10 and the neutralizing anti-TGF-# mAb, 1Dll.16 on stroma morphology. Marrow cells were grown in the absence 
or presence of ILA0 (2.5  ×  103 U/ml) or 1Dll.16 (10 ~g/ml) and examined in light microscopy on day 15 (A, C, and E) and in scanning 
electron microscopy on day 27 (B, D, and F). A, C, and E represent phase contrast micrographs of control, IL-10 and IDII.16 treated 
cultures, respectively. B, D, and F represent scanning electron microscopy of control, IL-10  and 1Dll.16 treated cultures, respectively. 
The mineralized collagenous extracellular matrix in the control culture (B) is indicated by white arrow heads. Bars: (A, C, and E) 22 
gin;  (C and F) 9 ~m; (D) 11 #m. 
sents the complete lack of biologically active TGF-~I in the 
culture system. This illustrates once more that mRNA levels 
may provide incomplete information about the amount of bi- 
ologically active material that is present in a given culture 
system. Direct proof for the role of TGF-~I in IL-10 activity, 
appeared from the observation that the IL-10-induced sup- 
pression of bone protein synthesis and mineralization could 
be reversed by adding exogenous biologically active TGF-~I. 
This illustrates the crucial role of  TGF-/5'I during in vitro osteo- 
genic differentiation and correlates with previous findings il- 
lustrating the enhancing effect of TGF-/~I  on extracellular 
matrix formation by osteoblasts (Centrella et al.,  1986). 
Of particular interest is the observation that biologically 
latent as well as active TGF-ffl are present in the culture su- 
pernatants. It is not clear whether TGF-/5'I is synthesized as 
an active form or whether latent TGF-ffl is activated after 
secretion. Since osteoblasts synthesize latent TGF-/3 (Pfeil- 
schifter et al.,  1987;  Bonewald et al.,  1991) which incor- 
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Subburaman, 1990), we like to support the latter possibility. 
Hence, this implies an endogenous activation mechanism 
present in the mouse bone marrow culture system. More than 
one mode of activation of latent TGF-/~ has been demon- 
strated including acidification, heat, and protease treatment. 
Among others, plasmin was found to convert latent TGF-/~ 
into a 25-kD form representing active TGF-/~ (Lyons et al., 
1990).  Osteoblasts produce plasminogen activator and con- 
sequently are able to convert latent TGF-/3 into its active 
form (Hamilton et al.,  1985). 
"I'GF-/5'I is present throughout the culture period but is 
maximally synthesized around days 6  and 27.  A  relevant 
question is whether in vitro osteogenic differentiation re- 
quires TGF-/~I to be present continuously or only during a 
restricted time frame of the culture. In a previous report we 
emphasized that IL-10 suppressed bone protein synthesis and 
mineralization only when added at the beginning of the cul- 
ture (Van Vlasselaer et al., 1993). In the context of the pres- 
ent data this implicates a role for TGF-/~I during the early 
steps of osteogenic differentiation. The latter was illustrated 
by the observation that 1Dll.16 elicited a suppressive effect 
on bone protein synthesis and mineralization when added be- 
fore day 10 of the culture but not when added at later time 
points. Hence, especially the first increase of TGF-~I secre- 
tion around day 6 appears to be necessary. Looking at the 
kinetics of bone protein synthesis this implicates that endog- 
enous TGF-/~I induces osteogenic differentiation at a time 
point which precedes the expression of the earliest bone 
related marker, ALP. Considering that all components of the 
skeleton  are  derived  from  undifferentiated mesenchymal 
cells, we like to envisage TGF-B1 as a commitment factor 
which drives these "naive", "uncommitted" ceils towards os- 
teogenic differentiation. 
The progression of  mesenchymal cells through the distinct 
steps of osteogenic differentiation is characterized by three 
distinct periods: proliferation, extracellular matrix matura- 
tion, and mineralization (Owen et al.,  1990;  Falla et al., 
1993).  The present data show that TGF-~I is active before 
[3H]TdR uptake increases. Consequently, the role of TGF- 
/5'1 may merely be the stimulation of cell proliferation. How- 
ever, TGF-/~I appears not to function as a mitogenic trigger 
for osteoprogenitor cells since [3H]TdR incorporation was 
comparable between control and 1I)11.16 treated cultures. In 
addition,  IDll.16 did not affect the number of CFU-F of 
which ,,o30% represent cells with osteogenic potential (Falla 
et ai.,  1993).  Moreover, [3H]TdR uptake by the pre-osteo- 
blastic cell lines MN7 (Mathieu et al.,  1992) and MC3T3 
(Sudo et al., 1983) was not altered in the presence of 1Dll.16. 
At first sight this may contradict previous data illustrating 
TGF-/31's stimulatory effect on osteoblast proliferation (Hill 
et al., 1986; Gehron-Robey et al., 1987).  However, we like 
to emphasize that TGF-/~ elicits both stimulatory and sup- 
pressive effects on osteoblast proliferation depending on the 
differentiation stage of the particular cells (Centralla et al., 
1987a). Hence, differential effects of TGF-/~I on the prolifera- 
tion of mature osteoblasts and immature mesenchymal cells 
of the bone marrow cannot be ruled out at this point. 
Apart from their suppressive activity, IL-10 and 1Dll.16 
induced comparable changes in the morphology of  cultivated 
marrow.  Whereas  control  cultures  contained  mainly flat 
adherent cells with a fibroblastoid morphology, IL-10 and 
1D11.16 treated cultures were characterized by the presence 
of significant numbers of semi- and non-adherent cells. In 
addition, scanning electron microscopy revealed that in con- 
trast to the control cultures, no mineralized matrix was pres- 
ent in the IL-10 and ID11.16 treated cultures. This illustrates 
once more that inhibiting TGF-~I activity results in a sup- 
pressive effect on bone protein synthesis and mineralization 
and underlines the importance of TGF-/~I during extracellu- 
lar matrix formation (Hill et al.,  1986;  Centrella et al., 
1987b).  In addition, IL-10 and 1Dll.16 treated cultures re- 
vealed the presence of "blanket stroma" and cell aggregates 
resembling the "cobblestone areas" described by Allen and 
Dexter (1984) suggesting hematopoietic activity in these cul- 
tures. Recent studies in our laboratory support the latter idea 
and showed the long term generation of myeloid cells in 
IL-10 and  1Dll.16  treated osteogenic cultures (Van Vlas- 
selaer,  P., R. Van Den Heuvel, B. Borremans, J. R. Dasch, 
and R. de Waal Malefyt, manuscript submitted for publica- 
tion).  Collectively these  data indicate that IL-10  inhibits 
bone protein synthesis and mineralization in mouse bone 
marrow cultures by blocking endogenous TGF-/~I produc- 
tion which is required for the osteogenic commitment of un- 
differentiated mesenchymal cells. 
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